Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study	Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, breast carcinoma in situ, breast disorder, breast neoplasm, carcinoma, epithelial neoplasm, in situ carcinoma, neoplasm, skin disorder	Enrolling by invitation	Phase 2	2025-11-28		NCT06843681

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Peking University Shenzhen Hospital	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	285

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Guangzhou	China	13